Bio-Rad Laboratories, Inc. Class A Common Stock vs Stanley Black & Decker, Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.89 (market cap $8.04B), while Stanley Black & Decker, Inc. trades at $88.43 (market cap $13.58B). The key difference: Stanley Black & Decker, Inc. is the larger of the two by market cap, and Stanley Black & Decker, Inc. pays a 3.8% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | SWK | |
|---|---|---|
Market Cap | $8.04B | $13.58B |
Sector | Health | — |
52-Week High | $339.75 | $94.12 |
52-Week Low | $241.71 | $62.12 |
Enterprise Value | $7.85B | $19.75B |
Dividend Yield | — | 3.8% |
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Stanley Black & Decker (SWK) trades at $86.53, down 1.92% on the day, with a bearish technical signal but recent earnings beats. The company shows modest revenue of $15.13B in 2025 and a net income margin of 2.44%, though profitability metrics like ROE at 4.17% remain subdued. A dividend of $0.83 was recently declared, with cash flow from operations positive at $971.20M. Analyst consensus is mixed with 43% buy ratings but a price target below the current price.
SWK faces headwinds from weak Tools & Outdoor demand and high debt, though cost-saving efforts and aerospace growth offer upside. The stock's valuation at a P/E of 35.46 appears stretched relative to earnings growth, suggesting cautious optimism hinges on execution improvements and debt reduction. Risks include consumer sentiment and interest rate sensitivity.
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →